Please login to the form below

Not currently logged in
Email:
Password:

Pfizer phase III Lyrica success

Pfizer has recorded positive results in a phase III trial of fibromyalgia treatment Lyrica

Pfizer has recorded positive results in a phase III trial of Lyrica (pregabalin), a potential new treatment for fibromyalgia -  a disabling disorder that adversely affects quality of life.

The study demonstrated a statistically significant reduction in the endpoint mean pain score recorded by participants, with the drug demonstrating efficacy and safety.

The drug was compared to placebo, with 501 subjects involved across 45 investigative sites in Japan.

"We are pleased with the top-line results of this study and look forward to more fully understanding the potential benefits that Lyrica may bring to fibromyalgia patients in Japan," said Dr Akihisa Harada, vice president, head of development, at Pfizer Japan.

The most common adverse events in the study were somnolence, dizziness, weight increased, constipation, feeling abnormal, edema peripheral and blurred vision.

7th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PharmiWeb Solutions

PharmiWeb Solutions creates, delivers and manages digital solutions for the pharmaceutical and healthcare segment. From digital marketing, to patient education...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics